AMISULPRIDE
Schizophrenia, Treatment-Resistant
University of California, Los AngelesSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Schizophrenia, Treatment-Resistant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Dr. Stavroula Rakitzi | Phase 4 | BB |
Risperdal Dr. Stavroula Rakitzi | Phase 4 | BB |
Clozapine Dr. Stavroula Rakitzi | Phase 4 | BB |
Dextromethorphan All India Institute of Medical Sciences, Bhubaneswar | Phase 4 | BB |
Paliperidone Palmitate 3-Month Formulation Dr. Stavroula Rakitzi | Phase 4 | B |
View all 23 →
Same molecule, other indications
AMISULPRIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →